Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Novo taps Ascendis in $285m GLP-1 deal Danish pharma giant Novo Nordisk will use Ascendis TransCon platform to produce its once-monthly GLP-1 receptor agonist candidate
This suggested that the PI3K/AKT pathway is increased in Gclc -deficient FoB, and in turn can sustain increased mTORC1 activity
Cannot redeclare control with same name "grid_1_qv_background_hover_color_stop"
We even took the extra step to become Leaping Bunny certified and make all of our products vegan (youre welcome.) Are your products fragrance free
(PubMed) Wilhelm SM, Rjater RG, Kale-Pradhan PB
US$ 26.91
![GLP-1 (7-36), [125I]-, 10µCi (370kBq)](https://resources.revvity.com/images/radiochemical-container-and-vial-blk-clr.jpg?format=auto&width=520)
US$ 25.92
US$ 27.82
US$ 29.45
US$ 26.14
US$ 20.92
US$ 22.83
US$ 22.79
US$ 22.83
